Our pivotal study included US and OUS centers to evaluate the safety and effectiveness of Agili-C compared to the current surgical standard of care in traumatic and arthritic lesions. The study is prospective, multicenter, open-label, randomized and controlled. The results at two years demonstrate the ability of Agili-C to provides clinically meaningful outcomes, superior to the surgical standard of care.